SCHEMBL6943783

SCHEMBL6943783

O=C(NCc1cc2ccccc2s1)c1cc([N+](=O)[O-])ccc1N[C@H]1CC[C@@H](O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
KMT2A Q03164 5/20 0.44
HPGD P15428 2/20 0.40
TP53 P04637 1/20 0.40
MEN1 O00255 3/20 0.40
PRSS12 P56730 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
PKM P14618 2/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 1/20 0.37
FLT3 P36888 2/20 0.37
TYRO3 Q06418 2/20 0.37
MERTK Q12866 2/20 0.37
GAS6 Q14393 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943781 1.00 MAPT (0.49) MAPTKMT2AHPGDTP53MEN1
SCHEMBL6937260 0.83 MAPT (0.59) MAPTKMT2AHPGDMEN1SMN1; SMN2
SCHEMBL6937256 0.83 MAPT (0.59) MAPTKMT2AHPGDMEN1SMN1; SMN2
SCHEMBL6940136 0.82 FLT3 (0.53) MAPTKMT2AMEN1SMN1; SMN2PKM
SCHEMBL6943641 0.82 FLT3 (0.52) MAPTKMT2AMEN1SMN1; SMN2PKM
SCHEMBL6940140 0.82 FLT3 (0.53) MAPTKMT2AMEN1SMN1; SMN2PKM
SCHEMBL6943644 0.82 FLT3 (0.52) MAPTKMT2AMEN1SMN1; SMN2PKM
SCHEMBL6938997 0.82 MAPT (0.51) MAPTKMT2AMEN1GAARAB9A
SCHEMBL6938994 0.82 MAPT (0.51) MAPTKMT2AMEN1GAARAB9A
SCHEMBL6937063 0.81 CYP1A2 (0.55) MAPTKMT2AHPGDMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPT 4706/4885KMT2A 1991/4885HPGD 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.